Autologous stem cell transplantation for HIV-associated lymphoma

Blood - Tập 98 - Trang 3857-3859 - 2001
Amrita Krishnan1, Arturo Molina1, John Zaia1, Auayporn Nademanee1, Neil Kogut1, Joseph Rosenthal1, Doni Woo1, Stephen J. Forman1
1From the Division of Hematology and Bone Marrow Transplantation, Division of Pediatrics (Virology and Infectious Disease, Bone Marrow Transplantation); City of Hope Medical Center, Duarte, California; The City of Hope–Southern California Kaiser Permanente Bone Marrow Transplant Program.

Tóm tắt

Abstract Is peripheral stem cell mobilization followed by autologous stem cell transplantation (ASCT) feasible in patients with human immunodeficiency virus (HIV)– associated lymphoma (HIV-L)? Studies have demonstrated that, in the HIV- negative (HIV−) setting, ASCT may improve lymphoma-free survival in high-risk non-Hodgkin lymphoma (NHL) or relapsed Hodgkin disease (HD) and NHL. Given the poor prognosis of HIV-L with conventional chemotherapy, this dose-intensive approach was explored. Nine patients with HIV-HD or NHL mobilized a median of 10.6 × 106 CD34+ cells/kg and engrafted after ASCT. CD4 counts recovered to pretransplantation levels and HIV viral loads were controlled in patients compliant with antiretroviral therapy. Seven of 9 patients remain in remission from their lymphoma at a median of 19 months after transplantation. Thus, patients with HIV-L on antiretroviral therapy can engraft following ASCT. Prolonged lymphoma remissions, without significant compromise of immune function, can be seen, suggesting that ASCT can be used in selected patients with HIV-L.

Tài liệu tham khảo

Bower, 2000, Changes in AIDS related lymphoma (ARL) in the era of highly active antiretroviral therapy (HAART) [abstract]., Proc Am Soc Clin Oncol., 19, 17a Jacobson, 1999, Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1 infected individuals., J Acquir Immune Defic Syndr., 21, S34 Levine, 2000, Evolving characteristics of AIDS-related lymphoma., Blood., 96, 4084, 10.1182/blood.V96.13.4084 Matthews, 2000, Changes in acquired immunodeficiency syndrome-related since the introduction of highly active antiretroviral therapy., Blood., 96, 2730, 10.1182/blood.V96.8.2730 Cote, 1997, Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden., Int J Cancer., 73, 645, 10.1002/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.0.CO;2-X Re, 2000, Increased incidence in HIV-associated Hodgkin's disease in the era of highly active antiretroviral therapy (HAART) [abstract]., Blood., 96, 830a Kaplan, 1997, Low-dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection., N Engl J Med., 336, 1641, 10.1056/NEJM199706053362304 Little, 1999, Dose adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma [abstract]., Proc Am Soc Clin Oncol., 18, 10a Errante, 1999, Feasibility of the integration of Stanford V chemotherapy (CT) regimen with highly active antiretroviral therapy (HAART) and G-CSF in patients (pts) with Hodgkin's disease and HIV infection (HD-HIV) [abstract]., Proc Am Soc Clin Oncol., 18, 11a Molina, 2000, High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy., Cancer., 89, 680, 10.1002/1097-0142(20000801)89:3<680::AID-CNCR25>3.0.CO;2-W Gabarre, 2000, High dose therapy and autologous haematopoietic stem cell transplantation for HIV-1 associated lymphoma., Lancet., 335, 1071, 10.1016/S0140-6736(00)02041-9 Philip, 1995, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma., N Engl J Med., 333, 1540, 10.1056/NEJM199512073332305 Nademanee, 1997, Results of high-dose therapy and autologous bone marrow/stem cell transplantation in poor-risk intermediate and high-grade lymphoma: international index high and high intermediate risk group., Blood., 90, 3844, 10.1182/blood.V90.10.3844 Haioun, 2000, Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87–2 protocol—a Groupe d'Etude des Lymphomes de l'Adulte Study., J Clin Oncol., 18, 3025, 10.1200/JCO.2000.18.16.3025 Shipp, 1993, A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project., N Engl J Med., 329, 987, 10.1056/NEJM199309303291402 Zaia, 16-18, 2000, Treatment of AIDS lymphoma with high dose chemotherapy and genetically modified stem cells: a model for evaluation of gene therapy [abstract]. Nademanee, 1995, High dose chemotherapy with or without total body-irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors., Blood., 85, 1381, 10.1182/blood.V85.5.1381.bloodjournal8551381 Flexner, 1998, HIV protease inhibitors., N Engl J Med., 338, 1281, 10.1056/NEJM199804303381808 Navarro, 1998, International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP: a multivariate study of 46 patients., Haematologica., 83, 508 Weiss, 2000, HIV related lymphoma: changes in immune parameters and viral load during chemotherapy [abstract]., Blood., 96, 134a
Thông tin
Thông tin xuất bản

Blood

Tập 98

3857-3859

Thông tin tác giả